Ionis Pharmaceuticals vs TG Therapeutics
IONS and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IONS and TGTX compare
TG Therapeutics is the larger company, worth 1.3 times as much as Ionis Pharmaceuticals ($9.4B against $7.2B).
TG Therapeutics grew revenue faster over the last twelve months (76.1% versus −7.4% for Ionis Pharmaceuticals).
TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with −64.7% at Ionis Pharmaceuticals.
TG Therapeutics scores higher on the StockData Score (10 against 3 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IONS | TGTX |
|---|---|---|
| Size and price | ||
| Market cap | $7.2B | $9.4B |
| Share price | $43.52 | $61.18 |
| Change, 1 year | −39.5% | 81.1% |
| Change, 5 years | 29.2% | 72.3% |
| Beta (5Y) | 0.71 | 1.73 |
| Employees | 1,402 | 399 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 4 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.3× |
| P/S | 8.3× (better) | 11.7× |
| P/B | 16.4× | 15.5× (better) |
| EV/EBITDA | – | 69.6× |
| P/FCF | – | 539× |
| FCF yield | −7.8% | 0.19% (better) |
| Fair value | $28.12 | $76.21 |
| Margin of safety | −54.7% | 19.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −7.4% | 76.1% (better) |
| Revenue growth, 5Y average | 5.3% | 427% (better) |
| Net income growth (TTM) | – | 630% |
| EPS growth (TTM) | – | 641% |
| Profitability | ||
| Gross margin | 98.2% (better) | 82.4% |
| Operating margin | −68.0% | 17.1% (better) |
| Net margin | −64.7% | 55.2% (better) |
| FCF margin | −64.2% | 2.2% (better) |
| Return on equity | −105% | 100% (better) |
| Return on invested capital | – | 27.8% |
| Financial health | ||
| Debt / equity | – | 1.23 |
| Net debt / EBITDA | – | 0.98 |
| Interest coverage | −31.6× | 3.6× (better) |
| Current ratio | 7.89 (better) | 4.27 |
| Altman Z-score | 0.88 | 5.93 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.9% |
| Shareholder yield | 0.00% | 1.9% (better) |
| Ownership | ||
| Held by institutions | 108% | 72.6% |
| Held by insiders | 0.80% | 16.1% |
| Insider net buying, 12 months | −$123M | −$438K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 13.7% | 23.8% |
Go deeper
- IONS stock overview
- IONS income statement
- IONS valuation and score
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.